Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Antibacterials

Drug resistance and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Amadesi S, et al. Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment. International Journal of Antimicrobial Agents 63: No. 4, Jan 2024. Available from: URL: https://dx.doi.org/10.1016/j.ijantimicag.2024.107107 Amadesi S, et al. Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment. International Journal of Antimicrobial Agents 63: No. 4, Jan 2024. Available from: URL: https://dx.doi.org/10.1016/j.ijantimicag.2024.107107
Metadaten
Titel
Antibacterials
Drug resistance and lack of efficacy
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55425-1

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Methylphenidate

Case report

Sodium-valproate

Case report

Mepolizumab

Case report

Dexamethasone